Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.67 |
| ▸ | MAOB | P27338 | 9/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SCN1A | P35498 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13930969 | 0.89 | ALDH1A1 (0.62) | HRH3ALDH1A1CYP1A2CHRM2CHRM1 | |
| SCHEMBL14791911 | 0.87 | HRH3 (0.86) | HRH3MAOB | |
| SCHEMBL4404318 | 0.87 | KDM4E (0.75) | HRH3ALDH1A1CYP1A2CHRM2CHRM1 | |
| SCHEMBL13259757 | 0.86 | HRH3 (0.86) | HRH3MAOB | |
| SCHEMBL13498470 | 0.84 | ALDH1A1 (0.58) | HRH3ALDH1A1CYP1A2CHRM2CHRM1 | |
| SCHEMBL13952428 | 0.83 | HRH3 (0.67) | HRH3MAOB | |
| SCHEMBL21025869 | 0.83 | HRH3 (0.67) | HRH3MAOB | |
| SCHEMBL29508217 | 0.82 | ALDH1A1 (0.88) | HRH3ALDH1A1CYP1A2CHRM2CHRM1 | |
| SCHEMBL12764930 | 0.81 | ALDH1A1 (0.61) | HRH3ALDH1A1CYP1A2CHRM2CHRM1 | |
| SCHEMBL21049830 | 0.80 | ALDH1A1 (0.63) | HRH3ALDH1A1CYP1A2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054472-A1 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof | TEIJIN PHARMA LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7473694-B2 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2009-01-06 | — | — | US | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054472-A1 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | HRH3 2746/4885MAOB 4400/4885ALDH1A1 2911/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | HRH3 2746/4885MAOB 4400/4885ALDH1A1 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.